Key Takeaways ServiceNow is expanding AI reach via partnerships with Microsoft, OpenAI and Anthropic.NOW leverages partners and marketplaces to drive AI adoption and larger enterprise deals.NOW's open architecture boosts integration, with revenues projected to grow over 20% in 2026.ServiceNow’s (NOW) expanding partnerships are significantly broadening its AI reach, strengthening the case for further upside. By collaborating with leading AI and cloud players like Microsoft, OpenAI and Anthropic, the company ...

Investment Rating - The report does not explicitly provide an investment rating for the biopharmaceutical industry Core Insights - Biopharmaceutical manufacturing is at a critical inflection point, with 64% of drug-launch delays in 2024 attributed to chemistry, manufacturing, and control issues, highlighting the need for improved integration from lab to line [27][34] - The adoption of intelligent technologies can significantly enhance operational efficiency, reduce costs, and accelerate time-to-market, with potential reductions in time-to-market by up to 40% and yield enhancements of over 400% in upstream processes [67][121] - Companies that modernize their manufacturing operations can capture three critical advantages: accelerated time-to-market, significantly lower production costs, and secure uninterrupted supply of medicines [37] Summary by Sections Current State: Progress Amid Persistent Challenges - The pharmaceutical sector is at a pivotal juncture in its digital transformation journey, with 35% of surveyed executives indicating their companies function as "connected organizations" [39] - Less than 10% of respondents reported operating in an "adaptive" environment, indicating a significant gap in digital maturity across organizations [39] Roadblocks to Scaling Digital Initiatives - Fragmented solutions and siloed initiatives hinder the scaling of digital capabilities, leading to limited ROI and a growing number of "digital dead ends" [52] - Companies face challenges in industrializing their digital capabilities, with many still operating in low-impact areas [58] Reinventing the Product Development Lifecycle - A bold vision is required to optimize the product development lifecycle, leveraging AI and intelligent technologies to enhance every stage from process development to regulatory submissions [59][61] - Adoption of intelligent technologies can lead to measurable gains in efficiency, with companies reporting improvements in day-to-day supply efficiency by 54% and expedited regulatory filings by 34% [41][67] Roadmap for Unlocking Value - The report outlines three key focus areas for successful digital transformation: lead with value, build a solid data-and-systems foundation, and reinvent workflows and ways of working [72] - Organizations that build a solid data foundation are 1.8 times more likely to achieve best-in-class performance [90] Future of Biopharma Production - The future of biopharma production is driven by intelligent technologies, which can expand revenue curves, shorten launch curves, and extend the lifecycle of therapies [121][122] - Early adopters of intelligent technologies have seen significant improvements in efficiency and cost reduction, yet many companies struggle with scaling these innovations [122][123]